- No open positions
- BiOrion has raised additional funding from one of its founders for a clinical phase 2 diagnostic-imaging program in cardiac fibrosis patients
- A consortium including BiOrion is awarded a EUROSTARS grant of a EUR 1.7 million for diagnostic imaging of colorectal cancer
- First patient enrolled in a PET-imaging study with BiOrion’s 68-Gallium labeled PDGF beta receptor binding bicyclic peptide BOT5035 in patients with organ fibrosis.
- BiOrion concluded investment by a consortium of investors including Pharma Connect Capital
No comments to show.